A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Non-alcoholic Steatohepatitis (NASH) Clinical Trial

Official title:

A Phase 1, Double Blind, Randomised, Placebo-Controlled, Multi-centre, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients With Non-alcoholic Steatohepatitis (NASH) With Fibrosis Stage 0-3 and Carriers of the PNPLA3 148M Risk Alleles

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04483947
• Other study ID #: D7830C00002
• Status: Completed
• Phase: Phase 1
• Start date: November 6, 2020
• Est. completion date: December 18, 2023

Study information

• Verified date: January 2024
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with Non-alcoholic Steatohepatitis (NASH) with fibrosis Stage 0 to 3 and who are carriers of the patatin-like phospholipase domain-containing 3 (PNPLA3) 148M risk alleles.

Description:

This study is a double blind, randomised, placebo-controlled, multi-centre study in participants with NASH and fibrosis stage between F0 (no fibrosis) and F3 (bridging fibrosis), and who are carriers of the PNPLA3 148M risk alleles.

The study will comprise of:

• An optional Pre-Screening Visit may be completed to determine PNPLA3 genotype and collect minimal baseline data and participants who are carriers of the PNPLA3 148M risk allele(s) will continue the study and enter the Screening Period.

• A Screening Period with a maximum of 60 days.

• For participants in all Cohorts, the dosing period will be 8 weeks during which participants will be resident of the study site for Dose 1 and Dose 3. Dose 1 will have participants reside at the study site from the day prior to study intervention administration (Day -1) until at least 2 days after study intervention administration with discharge on Day 3. Dose 2 will be administered at the study site on Day 29 with no overnight stay. Dose 3 will have participants reside at the study site from the day prior to study intervention administration (Day 56) until at least 2 days after study intervention administration with discharge on Day 59.

• Each participant will be followed for approximately 15 weeks post last dose.

The study will be performed at up to 30 study sites in the United States (US) and up to 5 study sites in Mexico. Approximately 80 participants comprising of male and female participants of non-childbearing potential may be enrolled into the first 4 cohorts of this study in order to achieve a target of 56 to 64 evaluable participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: December 18, 2023
• Est. primary completion date: December 18, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

For Cohorts 1 to 3:

• An MRI-PDFF =7% and one of the following:

• Previous liver biopsy: Acceptable if taken in the previous 3 years for fibrosis stages F0 to F2, or within the previous 1 year for stage F3; or

• Previous imaging results taken in the previous 2 years: An MRE between 2.55 kPa and 3.63 kPa, or a vibration-controlled transient elastography (VCTE) between 7.1 kPa and 11.9 kPa;

• Participants who are homozygous for rs738409 (PNPLA3 148M). Cohort 2 will enroll participants who are heterozygous for PNPLA3 148M.

For Cohort 4:

• An MRI-PDFF = 7% and participant's consent for a liver biopsy.

• Participants with suspected or confirmed Non-alcoholic fatty liver disease (NAFLD) or NASH are eligible for the Screening liver biopsy if they meet main protocol inclusion/exclusion criteria AND have any of the following:

Alanine aminotransferase > Upper Limit of Normal (ULN) but < 3 × ULN, OR Imaging demonstrating hepatic steatosis including attenuation parameter (CAP) > 290dB/m, OR A Magnetic resonance elastography (MRE) between 2.55 kPa and 3.63 kPa, or a vibration-controlled transient elastography (VCTE) between 7.1 kPa and 11.9 kPa.

• Histologic evidence of NAFLD or NASH with a NASH Activity Score (NAS) = 3 (independent of subcategory scoring) following Screening liver biopsy.

• Participants who are homozygous for rs738409 (PNPLA3 148M).

Exclusion Criteria:

• History of liver transplant, or current placement on a liver transplant list (this may be checked at the optional Pre-Screening Visit).

• History or presence of hepatic disease (with the exception of hepatic steatosis, NASH) or evidence of other known forms of known chronic liver disease such as alcoholic liver disease, hepatitis B, primary biliary cirrhosis, primary sclerotic cirrhosis, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (this may be checked at the optional Pre-Screening Visit).

• Histological or imaging (MRE or VCTE) evidence of cirrhosis.

• Participants with history or pre-existing renal disease, as defined below:

• estimated glomerular filtration rate < 60 mL/min/1.73 m^2 (calculated using the Chronic Kidney Disease Epidemiology Collaboration formula)

• Blood dyscrasias with increased risk of bleeding including idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura or symptoms of increased risk of bleeding (frequent bleeding gums or nose bleeds).

• History of major bleed or high-risk of bleeding diathesis.

Related Conditions & MeSH terms

• Fatty Liver
• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis (NASH)

Intervention

Drug:
• AZD2693
Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).

Other:
• Placebo
Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort

Locations

Country	Name	City	State
United States	Research Site	Arlington	Texas
United States	Research Site	Chula Vista	California
United States	Research Site	Columbus	Ohio
United States	Research Site	Dallas	Texas
United States	Research Site	Doral	Florida
United States	Research Site	Hershey	Pennsylvania
United States	Research Site	Hialeah	Florida
United States	Research Site	Hialeah	Florida
United States	Research Site	Indianapolis	Indiana
United States	Research Site	La Mesa	California
United States	Research Site	Miami Lakes	Florida
United States	Research Site	Montclair	California
United States	Research Site	Morehead City	North Carolina
United States	Research Site	San Antonio	Texas
United States	Research Site	San Antonio	Texas
United States	Research Site	San Diego	California

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	Parexel

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events		Up to 32 weeks (From Screening to Final Visit)
Secondary	Absolute change from baseline to Week 8 and Week 12 in liver fat content (LFC)		Baseline (Day 1), Week 8, Week 12
Secondary	Percent change from baseline to Week 8 and Week 12 in liver fat content (LFC)		Baseline (Day 1), Week 8, Week 12
Secondary	Absolute change from baseline in Alanine Aminotransferase		Up to 32 weeks (From Pre-Screening to Final Visit)
Secondary	Percent change from baseline in Alanine Aminotransferase		Up to 32 weeks (From Pre-Screening to Final Visit)
Secondary	Absolute change from baseline in Aspartate Aminotransferase		Up to 32 weeks (From Pre-Screening to Final Visit)
Secondary	Percent change from baseline in Aspartate Aminotransferase		Up to 32 weeks (From Pre-Screening to Final Visit)
Secondary	Absolute change from baseline in Gamma Glutamyl Transferase		Up to 32 weeks (From Pre-Screening to Final Visit)
Secondary	Percent change from baseline in Gamma Glutamyl Transferase		Up to 32 weeks (From Pre-Screening to Final Visit)
Secondary	Absolute change from baseline in Enhanced Liver Fibrosis (ELF) score		Up to 32 weeks (From Pre-Screening to Final Visit)
Secondary	Percent change from baseline in ELF score		Up to 32 weeks (From Pre-Screening to Final Visit)
Secondary	Absolute change from baseline in plasma pharmacodynamic biomarker		Days 1, 8, 29, 36, 50, 64, and 78
Secondary	Percent change from baseline in plasma pharmacodynamic biomarker		Days 1, 8, 29, 36, 50, 64, and 78
Secondary	Absolute change from baseline in disease-specific biomarkers		Days 1, 8, 29, 36, 50, 64, and 78
Secondary	Percentage change from baseline in disease-specific biomarkers		Days 1, 8, 29, 36, 50, 64, and 78
Secondary	Absolute change from baseline ß-Hydroxybutyrate and lipid profile		Days 1, 8, 29, 36, 50, 64, and 78
Secondary	Percent change from baseline ß-Hydroxybutyrate and lipid profile		Days 1, 8, 29, 36, 50, 64, and 78
Secondary	Maximum observed plasma drug concentration (Cmax)		Day 1 to Day 162
Secondary	Time to reach maximum observed plasma concentration (tmax)		Day 1 to Day 162
Secondary	Terminal elimination rate constant, estimated by log-linear least-squares regression of the terminal part of the concentration-time curve (?z)		Day 1 to Day 162
Secondary	Apparent terminal elimination half-life associated with the terminal slope (?z) of the semi-logarithmic concentration-time curve, estimated as (ln2)/?z (t½?z)		Day 1 to Day 162
Secondary	Area under the plasma concentration-time curve from time zero to 48 hours after dosing (AUC(0-48h))		Day 1 to Day 162
Secondary	Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUClast)		Day 1 to Day 162
Secondary	Area under the concentration-time curve from time zero extrapolated to infinity. AUC is estimated by AUClast + Clast/?z where Clast is the last observed quantifiable concentration (AUC)		Day 1 to Day 162
Secondary	Apparent total body clearance of drug from plasma after extravascular administration calculated as Dose/AUC (CL/F)		Day 1 to Day 162
Secondary	Mean residence time (MRT)		Day 1 to Day 162
Secondary	Time delay between drug administration and the first observed concentration in plasma (tlag)		Day 1 to Day 162
Secondary	Apparent volume of distribution for parent drug at terminal phase (extravascular administration), estimated by dividing the apparent clearance (CL/F) by ?z (Vz/F)		Day 1 to Day 162
Secondary	Area under the plasma concentration-time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (AUClast/D)		Day 1 to Day 162
Secondary	Area under the plasma concentration-time curve from time zero extrapolated to infinity divided by the dose administered (AUC/D)		Day 1 to Day 162
Secondary	Observed maximum plasma concentration divided by the dose administered (Cmax/D)		Day 1 to Day 162
Secondary	Time of the last quantifiable concentration (tlast)		Day 1 to Day 162
Secondary	Maximum observed plasma drug concentration at steady state (Cssmax)		Day 1 to Day 162
Secondary	Minimum observed drug concentration at steady state (Cssmin)		Day 1 to Day 162
Secondary	Time to reach maximum observed plasma concentration at steady state (tssmax)		Day 1 to Day 162
Secondary	Area under the concentration-time curve in the dose interval (AUCss)		Day 1 to Day 162
Secondary	Apparent total body clearance of drug from plasma after extravascular administration calculated as Dose/AUCss (CLss/F)		Day 1 to Day 162
Secondary	Area under the plasma concentration-time curve from time zero extrapolated to infinity divided by the dose administered (AUCss/D)		Day 1 to Day 162
Secondary	Observed maximum plasma concentration divided by the dose administered (Cssmax/D)		Day 1 to Day 162
Secondary	Accumulation ratio based on Cmax (RacCmax)		Day 1 to Day 162
Secondary	Accumulation ratio based on AUC (RacAUC)		Day 1 to Day 162
Secondary	Temporal change parameter in systemic exposure (TCP)		Day 1 to Day 162
Secondary	Amount of analyte excreted into the urine from time t1 to t2 (Ae(t1-t2))		Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Secondary	Cumulative amount of analyte excreted from time zero through the last sampling interval (Ae(0-last))		Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Secondary	Fraction of dose excreted unchanged into the urine from time t1 to t2 (fe(t1-t2))		Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Secondary	Cumulative fraction (%) of dose excreted unchanged into the urine from time zero to the last measured time point (fe(0-last))		Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Secondary	Renal clearance of drug from plasma, estimated by dividing Ae(0-t) by AUC(0-t) where the 0-t interval is the same for both Ae and AUC (CLR)		Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Secondary	Change from placebo to Week 10 in PNPLA3 messenger ribonucleic acid (mRNA) and protein expression (Cohort 4 only)		Week 10
Secondary	Change from baseline to Week 10 in PNPLA3 mRNA and protein expression (Cohort 4 only)		Baseline, Week 10